FindTrial
Sign In

Ropidoxuridine

DRUG4 trials

Sponsors

National Cancer Institute (NCI), Shuttle Pharmaceuticals, Inc.

Conditions

Advanced Bile Duct CarcinomaGlioblastoma, IDH-wildtypeHematopoietic and Lymphoid Cell NeoplasmLocally Advanced Rectal CarcinomaMalignant Solid NeoplasmMetastatic Malignant Neoplasm in the BrainRectal AdenocarcinomaStage II Esophageal Cancer AJCC v7

Phase 1

Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
Active, not recruitingNCT02381561
National Cancer Institute (NCI)Advanced Bile Duct Carcinoma, Stage IIA Esophageal Cancer AJCC v7, Stage IIA Pancreatic Cancer AJCC v6 and v7 +38
Start: 2016-02-01End: 2027-03-14Updated: 2026-04-03
Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
Active, not recruitingNCT02993146
National Cancer Institute (NCI)Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain
Start: 2017-05-08End: 2026-10-03Updated: 2025-10-29
Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer
TerminatedNCT04406857
National Cancer Institute (NCI)Locally Advanced Rectal Carcinoma, Rectal Adenocarcinoma, Stage III Rectal Cancer AJCC v8 +1
Start: 2021-03-17End: 2023-01-18Updated: 2025-02-26

Phase 2

Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
TerminatedNCT06359379
Shuttle Pharmaceuticals, Inc.Glioblastoma, IDH-wildtype
Start: 2024-09-02End: 2025-12-01Updated: 2025-12-18

Related Papers

A case report of typhlitis during novel use of ropidoxuridine-capecitabine-radiotherapy for treatment-naïve rectal cancer.
2023-06-27